Log in
Enquire now
‌

US Patent 11353458 Prognostic method

Patent 11353458 was granted and assigned to GlaxoSmithKline on June, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
GlaxoSmithKline
GlaxoSmithKline
0
Date Filed
October 28, 2016
0
Date of Patent
June 7, 2022
0
Patent Applicant
GlaxoSmithKline
GlaxoSmithKline
0
Patent Application Number
15771622
0
Patent Citations Received
‌
US Patent 11840575 Engineered immune cells targeting BCMA and their uses thereof
0
Patent Inventor Names
Danton Bounds
0
Katherine (Nee Sully) Nevin
0
Kwee L. Yong
0
Laura M. Seestaller-Wehr
0
Lee McCahon
0
Lydia Lee
0
Manuel Rodriguez-Justo
0
Patrick A. Mayes
0
William E. Fieles
0
Fiona M. Germaschewski
0
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11353458
0
Patent Primary Examiner
‌
Hong Sang
0
CPC Code
‌
G01N 2800/52
0
‌
A61K 39/395
0
‌
C07K 16/2878
0
‌
G01N 15/14
0
‌
G01N 2333/70578
0

Find more entities like US Patent 11353458 Prognostic method

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us